S-1: Bioxytran Files for Resale of 18 Million Common Shares Following Agreement with Triton Funds LP

Bioxytran, a clinical-stage pharmaceutical company, has filed a registration statement for the resale of 18 million shares of its common stock by a selling stockholder, Triton Funds LP.

Summary

• Bioxytran, Inc., a clinical-stage pharmaceutical company, is registering the resale of 18 million shares of its common stock.
• The shares are being offered by Triton Funds LP, a selling stockholder, following a closing agreement.
• Bioxytran will not receive any proceeds from the sale of these shares by the selling stockholder.
• The company will receive proceeds from the sale of purchase shares pursuant to the closing agreement.
• The selling stockholder may offer the shares from time to time through public or private transactions at prevailing market prices or at privately negotiated prices.
• As of December 31, 2024, the last reported sale price of Bioxytran's common stock was $0.088 per share.
• The company has a limited trading market for its stock, and there is no assurance that a trading market will develop or be sustained.
• Bioxytran is focused on developing drugs to address hypoxia, with its lead candidate, BXT-25, targeting hypoxic conditions in the brain resulting from stroke.
• The company also has a subsidiary, Pharmalectin, developing a glyco-viral pharmaceutical, ProLectin, with emphasis on treating COVID-19.
• Bioxytran has incurred losses since its inception and has an accumulated deficit of $18,404,275 as of September 30, 2024.
• The company had $34,672 cash on hand as of September 30, 2024.
• Bioxytran needs to raise at least $3,700,000 to continue operations for the next 15 months, but funding at any level lower than $5,300,000 will delay the development of its technology and business.

Sentiment

Score: 4

Explanation: The document highlights significant risks and financial challenges, including a substantial accumulated deficit, limited cash, and dependence on future capital raises. While there are some positive developments in clinical trials, the overall sentiment is negative due to the company's financial instability and the speculative nature of its technology.

Positives

• The company is actively developing drug candidates for significant medical needs, including stroke and COVID-19.
• Bioxytran has completed animal testing for BXT-25, showing non-toxicity and full recovery in mice.
• Pharmalectin has completed Phase 2 trials for ProLectin, showing a 100% response rate in reducing viral load in COVID-19 patients.
• The company has received FDA approval for a Phase 2 clinical trial of ProLectin-M in the US.

Negatives

• Bioxytran has a limited operating history and has incurred losses since its inception.
• The company has a limited trading market for its stock, and there is no assurance that a trading market will develop or be sustained.
• The company has a significant accumulated deficit and limited cash on hand.
• The company is dependent on raising additional capital to continue operations and develop its products.
• The company's products are based on novel, unproven technologies, and there is no guarantee of FDA approval.

Risks

• The company's plan relies on its ability to obtain additional capital, and failure to do so may require it to cease operations.
• The company may never achieve profitability.
• The company's drug candidates are based on novel, unproven technologies, and clinical trials may not be successful.
• The company may experience delays in clinical trials or marketing approvals.
• The company faces substantial competition from other pharmaceutical and biotechnology companies.
• The company is dependent on key executives, and the loss of any of them could adversely affect operations.
• The company may be subject to product liability claims.
• The company may be unable to obtain or maintain adequate product liability insurance.
• The company may be unable to obtain adequate reimbursement from third-party payers.
• The company may be unable to protect its intellectual property.
• The company may be subject to claims of infringement of third-party intellectual property rights.
• The company's stock price may be volatile, and investors could lose all or part of their investment.
• The company may be unable to effectively use the net proceeds from this offering.
• The company's ability to use net operating loss carry-forwards may be limited.
• The company's management collectively owns a substantial majority of the company's stock, which may prevent investors from affecting matters involving the company.
• The company may not be able to report its financial results accurately and timely or to prevent fraud.
• The company's stock may be subject to the penny stock rules, which may reduce trading activity.
• The company may not pay dividends in the foreseeable future.
• The company's plan relies upon its ability to obtain additional sources of capital and financing.
• The company has a limited operating history, which makes it difficult to evaluate its current business and future prospects.
• The company will require additional financing to implement its business plan, which may not be available on favorable terms or at all, and the company may have to accept financing terms that would place restrictions on it.
• The company's products are based on novel, unproven technologies.
• Clinical trials are expensive, time-consuming and may not be successful.
• The company may be unable to obtain FDA or EMA approval of its products in development and, even if it does so and is also able to commercialize its products, it may never generate revenue sufficient to become profitable.
• The company will rely on third parties to conduct its clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.
• If the company experiences delays or difficulties in the enrollment of patients in clinical trials, its receipt of necessary regulatory approvals could be delayed or prevented.
• If serious adverse or unacceptable side effects are identified during the development of the company's drug candidate or the company observes limited efficacy, it may need to abandon or limit its development of some of its drug candidate.
• Even if the company's drug candidates receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, third-party payers and others in the medical community necessary for commercial success.
• If the company is unable to establish effective sales, marketing and distribution capabilities or enter into agreements with third parties with such capabilities, it may not be successful in commercializing its drug candidates if and when they are approved.
• The company faces substantial competition, which may result in others discovering, developing or commercializing competing products before or more successfully than the company does.
• The company's success depends upon its ability to retain key executives and to attract, retain, and motivate qualified personnel, and the loss of these persons could adversely affect its operations and results.
• The company's lack of operating experience may cause it difficulty in managing its growth which could lead to its inability to implement its business plan.
• The company will depend on third parties to manufacture and market its products and to design trial protocols, arrange for and monitor the clinical trials, and collect and analyze data.
• The company is exposed to product liability, pre-clinical and clinical liability risks which could place a substantial financial burden upon it, should it be sued.
• If users of the company's proposed products are unable to obtain adequate reimbursement from third-party payers or if new restrictive legislation is adopted, market acceptance of the company's proposed products may be limited, and the company may not achieve revenues.
• There are risks associated with the company's reliance on third parties for marketing, sales and distribution infrastructure and channels.
• The company will be subject to risks if it seeks to develop its own sales force.
• The company will need regulatory approvals to commercialize its products as drugs.
• The company's competitive position depends on protection of its intellectual property.
• The company may be unable to compete in its target marketplaces, which could impair its ability to generate revenues, thus causing a material adverse impact on its results of operations.
• The company may be unable to timely educate physicians regarding its proposed products in sufficient numbers to achieve its marketing plans or to achieve product acceptance.
• The company may be unable to obtain and maintain patent protection for its products, or if the scope of the patent protection obtained is not sufficiently broad, competitors could develop and commercialize products similar or identical to the company's, and the company's ability to successfully commercialize its products may be impaired.
• The company may become involved in lawsuits to protect or enforce its patents or other intellectual property, which could be expensive, time-consuming and ultimately unsuccessful.
• The company may be subject to claims by third parties asserting that its employees or it have misappropriated their intellectual property, or claiming ownership of what the company regards as its own intellectual property.
• If the company is unable to protect the confidentiality of its trade secrets, its business and competitive position would be harmed.
• Prior to this offering, the company had a limited public market for its shares of Common Stock and you may not be able to resell its shares at or above the price you paid, or at all.
• The company does not expect to pay dividends in the foreseeable future.
• Provisions in the Nevada Revised Statutes and the company's Bylaws could make it very difficult for an investor to bring any legal actions against the company's Directors or officers for violations of their fiduciary duties or could require the company to pay any amounts incurred by its Directors or officers in any such actions.
• Future sales of substantial amounts of the shares of Common Stock by existing Shareholders could adversely affect the price of the company's Common Stock.
• The market price of the company's Common Stock may be subject to fluctuation, and you could lose all or part of your investment.
• The company has broad discretion as to the use of the net proceeds from this offering and may not use them effectively.
• The financial and operational projections that the company may make from time to time are subject to inherent risks.
• An investment in the company may involve tax implications, and you are encouraged to consult your own advisors as neither the company nor any related party is offering any tax assurances or guidance regarding the company or your investment.
• The company's ability to use its net operating loss carry-forwards and certain other tax attributes may be limited.
• The company's Certificate of Incorporation permits blank check Preferred Stock, which can be designated by the company's Board of Directors without stockholder approval.
• The company's management collectively owns a substantial majority of the company's Common Stock.
• If the company fails to establish and maintain an effective system of internal control or disclosure controls and procedures are not effective, the company may not be able to report its financial results accurately and timely or to prevent fraud.
• If securities or industry analysts do not publish research or reports about the company, its business or its market, or if they make and then change their recommendations regarding the company's Common Stock adversely, the price of the company's Common Stock and trading volume could decline.
• In making your investment decision, you should understand that the company has not authorized any other party to provide you with information concerning the company or this offering.
• Common Stock that the company issues upon conversion of the promissory notes will dilute its existing stockholders and depress the market price of its Common Stock.
• The holders of the notes convertible into the company's Common Stock will pay less than the thenprevailing market price for its Common Stock.
• The price of the Common Stock the company is selling under this Offering is significantly higher than the conversion price of the Notes and the price of its Common Stock would likely drop to or below the conversion price of the Notes upon conversion by the noteholders.

Future Outlook

The company believes that it must raise not less than $3,700,000 in the current offering in addition to current cash on hand to be able to continue its business operations for approximately the next fifteen (15) months; however, funding at any level lower than $5,300,000 will delay the development of its technology and business.

Industry Context

The announcement is related to the pharmaceutical industry, specifically companies focused on developing novel therapeutics for unmet medical needs. The company is operating in a competitive landscape with other pharmaceutical and biotechnology companies.

Comparison to Industry Standards

• The company's reliance on third-party manufacturers and clinical research organizations is common in the biotechnology industry.
• The company's need for additional funding is typical for clinical-stage pharmaceutical companies.
• The company's focus on novel technologies and drug candidates is consistent with the industry's emphasis on innovation.
• The company's challenges in obtaining regulatory approvals and achieving market acceptance are common in the pharmaceutical industry.
• The company's need to raise additional capital is typical for clinical-stage pharmaceutical companies.
• The company's reliance on third-party manufacturers and clinical research organizations is common in the biotechnology industry.
• The company's focus on novel technologies and drug candidates is consistent with the industry's emphasis on innovation.
• The company's challenges in obtaining regulatory approvals and achieving market acceptance are common in the pharmaceutical industry.

Related Party Transactions

• The company has license agreements with two affiliated companies where the officers of the company hold a majority interest.
• The company has a loan agreement with an affiliate.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's financial instability and the speculative nature of its technology.
• Employees face uncertainty regarding the company's ability to continue operations and fund its development programs.
• Customers and patients may benefit from the development of new treatments for stroke and COVID-19, but there is no guarantee of success.
• Suppliers and creditors face the risk of non-payment due to the company's financial challenges.

Next Steps

• The company plans to initiate pre-clinical studies of BXT-25.
• The company plans to continue clinical trials for ProLectin.
• The company plans to seek additional funding to support its operations and development programs.

Key Dates

Keywords

Bioxytran, BXT-25, ProLectin, hypoxia, stroke, COVID-19, pharmaceutical, clinical trials, drug development, biotechnology, Acellular Oxygen Carrier, galectin antagonist, FDA approval, resale, Triton Funds LP